The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 27, 2024
Filed:
Aug. 05, 2019
Inserm (Institut National DE LA Santé ET DE LA Recherche Médicale), Paris, FR;
Université DE Caen Normandie, Caen, FR;
Université DE Bourgogne, Dijon, FR;
Carmen Garrido Fleury, Dijon, FR;
Gaetan Jego, Dijon, FR;
Daniel Gonzalez, Dijon, FR;
Anne-Sophie Voisin-Chiret, Caen, FR;
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MEDICALE), Paris, FR;
UNIVERSITÉ DE CAEN NORMANDIE, Caen, FR;
UNIVERSITÉ DE BOURGOGNE, Dijon, FR;
Abstract
HSP110 inhibitors bind directly to the nucleotide binding domain of HSP110 and then block the phosphorylation of STAT3, cancer cell growth or MyD88 stability. Aspects involve a compound of formula (I) for use in the treatment of a HSP110-associated cancer, for example colorectal cancer and lymphoma. An examplary compound was tested on a syngeneic model for which mouse colon cancer CT-26 cells were injected into Balb/c mice and on a NOD/SCID model in which mice were implanted with human colorectal cancer HCT116 cells. In those animals bearing a tumor, the compound induced tumor regression that was associated with the inhibition of other HSP110 reported tumorigenic functions (resistance to apoptosis, induction of pro-tumor macrophages). Further, the compound was tested on large B cell lymphoma cell lines (DLBCL) and it was able to alter the interaction between HSP110 and MyD88, which induces a degradation of the oncogene MyD88. Additionally, it has been shown that the compound acts synergistically with other anti-cancer agents, including with tyrosine kinase inhibitors like Ibrutinib.